Skip to main content

Advertisement

SpringerLink
Log in

Prevalence of cardiometabolic syndrome in HIV-infected persons: a systematic review

  • Review article
  • Published:
Journal of Diabetes & Metabolic Disorders Aims and scope Submit manuscript

Abstract

Introduction

HIV infected persons are twofold likely to experience a heart attack, stroke, and other forms of Cardiometabolic Syndrome (CMetS).

Methods

Electronic searches of databases (MEDLINE and Google Scholar) were queried for articles written in English from 2000 to 2019.

Results

In this review (16 publications), a total of 14,002 participants from 8 countries were included. Two continents contributed to 62.5% of the CMetS studies while 38.1% from Latin America and 24.4% from North America. The studies were conducted in 113 different centers, with an average study length of 2.8 years. The majority of the study designs were cross-sectional (62%) followed by a cohort study (25%) and clinical trials (12.5%). The mean age of the population enrolled was 41.9 years and 54.6% of the participants were males. The overall prevalence of CMetS using the National Cholesterol Education Adult Treatment Panel definition was 20.6%. Only 31.3% of the studies were reported using the International Diabetes Federation definition. Smoking and high blood pressure were reported as a risk factor in 62.5% of the studies, while diabetes (31.3%), family history of CMetS (25%), and cardiac vascular and cancer diseases were reported in 12.5% of the studies. The average duration of stay with HIV after confirmation was 5.23 + 1.4 (years + SD) and the median duration on HAART was 4.5 + 2.3 (years + SD).

Conclusions

CMetS was a common problem among HIV infected persons. Several RFs can contribute to the development of CMetS with smoking and hypertension highly interrelated.

PROSPERO-number

CRD42018107187.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Paik J II, Kotler DP. The prevalence and pathogenesis of diabetes mellitus in treated HIV-infection. Best Pract Res Clin Endocrinol Metab. 2011;25:469–78.

    PubMed  Google Scholar 

  2. Friis-Møller NWR, Reiss P, Thiébaut R, Kirk O, d'Arminio Monforte A, Pradier C, et al. Lundgren JD; DAD study group. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. AIDS. 2003;17(8):1179–93.

    PubMed  Google Scholar 

  3. Cockerham LSR, Zolopa A, Rimland D, Lewis CE, Bacchetti P, Grunfeld C, et al. Association of HIV infection, demographic, and cardiovascular risk factors with all-cause mortality in the recent HAART era. J Acquir Immune Defic Syndr. 2010;53:102–6.

    PubMed  Google Scholar 

  4. Oh DH, Ahn JY, et al. Metabolic complications among Korean patients with HIV infection: the Korea HIV/AIDS cohort study. J Korean Med Sci. 2017;32(8):1268–74. https://doi.org/10.3346/jkms.2017.32.8.1268.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Barbaro G, Di Lorenzo G, Grisorio B, Barbarini G, Baum M, Shor-Posner G, et al. Dilated cardiomyopathy in HIV-infected patients. N Engl J Med. 1999;1999(340):732–5.

    Google Scholar 

  6. Steven G. Deeks, Sharon R Lewin, Diane V Havlir. The end of AIDS: HIV infection as a chronic disease. Lancet. 2013;382(9903):1525–33.

    Google Scholar 

  7. Todowede OO, Mianda SZ, Sartorius B. Prevalence of metabolic syndrome among HIV-positive and HIV-negative populations in sub-Saharan Africa-a systematic review and meta-analysis. Syst Rev. 2019;8(1):4. https://doi.org/10.1186/s13643-018-0927-y.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Srivastava AK. Challenges in the treatment of cardiometabolic syndrome. Indian J Pharm. 2012;44(2):155–6. https://doi.org/10.4103/0253-7613.93579.

    Article  CAS  Google Scholar 

  9. Varriale P, Saravi G, Eliezer Hernandez A, Carbon F. Acute myocardial infarction in patients infected with human immunodeficiency virus. Am Heart J. 2004;147(1):55–9.

    CAS  PubMed  Google Scholar 

  10. Willard S. The nurse practitioner’s role in managing dyslipidemia and other cardiovascular risk factors in HIV-infected patients: impact of antiretroviral therapy. JANAC. 2006;17(1):7–17.

  11. Papakonstantinou E, Lambadiari V, Dimitriadis G, Zampelas A. Metabolic syndrome, and cardiometabolic risk factors. Curr Vasc Pharmacol. 2013;11(6):858–79.

    CAS  PubMed  Google Scholar 

  12. Naidu S, Ponnampalvanar S, Kamaruzzaman SB, Kamarulzaman A. Prevalence of metabolic syndrome among people living with HIV in developing countries: a systematic review. AIDS Patient Care STDs. 2017;31(1):1–13. https://doi.org/10.1089/apc.2016.0140.

    Article  PubMed  Google Scholar 

  13. Huang PL. A comprehensive definition of metabolic syndrome. Dis Model Mech. 2009;2(5–6):231–7. https://doi.org/10.1242/dmm.001180.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Moy FM, Bulgiba A. The modified NCEP ATP III criteria may be better than the IDF criteria in diagnosing Metabolic Syndrome among Malays in Kuala Lumpur. BMC Public Health. 2010;10:678. https://doi.org/10.1186/1471-2458-10-678.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Curr Opin Cardiol. 2006;21(1):1–6.

    PubMed  Google Scholar 

  16. Saltzgiver S, Nielson A, Costello H, Baker A, Chan J, Aguilar D. Dietary determinants of metabolic syndrome parameters differ by gender in college students. Nutrients. 2019;11(12):2892.

    PubMed Central  Google Scholar 

  17. Miao W, Shen Q. Advance in metabolic syndrome research [J]. Academic Journal of Second Military Medical University. 2004;25(3):1–12.

  18. Sasya M, Devi K, Babu JK, Rayappan B, Bosco J, Krishnan UM. Metabolic syndrome—an emerging constellation of risk factors: electrochemical detection strategies. Sensors. 2020;20(1):103.

    CAS  Google Scholar 

  19. Sa-Caputo DC, Paineiras-Domingos L, Oliveira R, Neves MF, Brandão A, Marin PJ, et al. Acute effects of whole-body vibration on the pain level, flexibility, and cardiovascular responses in individuals with metabolic syndrome. Dose-Response. 2018;16(4):1559325818802139.

    CAS  PubMed  PubMed Central  Google Scholar 

  20. Nguyen KA, Peer N, Mills EJ, Kengne AP. A meta-analysis of the metabolic syndrome prevalence in the global HIV-infected population. PLoS One. 2016;11(3):e0150970. https://doi.org/10.1371/journal.pone.0150970.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Judith S, Currier JDL, Carr A, Klein D, Sabin CA, Sax PE, et al. Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation. 2008;118:29–35. https://doi.org/10.1161/CIRCULATIONAHA.107.189624.

    Article  CAS  Google Scholar 

  22. Vernon LT, Babineau DC, Demko CA, Lederman MM, Wang X, Toossi Z, et al. A prospective cohort study of periodontal disease measures and cardiovascular disease markers in HIV-infected adults. AIDS Res Hum Retrovir. 2011;27(11):1157–66. https://doi.org/10.1089/AID.2010.0320.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Melzi S, Carenzi L, Cossu MV, Passerini S, Capetti A, Rizzardini G. Lipid metabolism and cardiovascular risk in HIV-1 infection and HAART: present and future problems. Cholesterol. 2010;2010:271504. https://doi.org/10.1155/2010/271504.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Ngatchou W, Lemogoum D, Ndobo P, Yagnigni E, Tiogou E, Nga E, et al. Increased burden and severity of the metabolic syndrome and arterial stiffness in treatment-naive HIV+ patients from Cameroon. Vasc Health Risk Manag. 2013;9:509.

    PubMed  PubMed Central  Google Scholar 

  25. Mayosi BM. Contemporary trends in the epidemiology and management of cardiomyopathy and pericarditis in sub-Saharan Africa. Heart. 2007;93(10):1176–83.

    PubMed  PubMed Central  Google Scholar 

  26. Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, et al. Contemporary definitions and classification of the cardiomyopathies. Circulation. 2006;113(14):1807–16.

    PubMed  Google Scholar 

  27. Triant VA. Cardiovascular disease and HIV infection. Curr HIV/AIDS Rep. 2013;10(3):199–206.

    PubMed  PubMed Central  Google Scholar 

  28. Barbaro G. Cardiovascular manifestations of HIV infection. Circulation. 2002;106(11):1420–5.

    PubMed  Google Scholar 

  29. Herskowitz A. Cardiomyopathy and other symptomatic heart diseases associated with HIV infection. Curr Opin Cardiol. 1996;11(3):325–31.

    CAS  PubMed  Google Scholar 

  30. Palella FJ, Phair JP. Cardiovascular disease in HIV infection. Curr Opin HIV AIDS. 2011;6(4):266–71.

    PubMed  PubMed Central  Google Scholar 

  31. Lorell B, Grossman W. Profiles in constrictive pericarditis, restrictive cardiomyopathy, and cardiac tamponade. In: Febige La, editor. Cardiac catheterization and angiography Third edition. Philadelphia: Harvard Medical School; 1986. p. 427–45.

  32. Grant I, Atkinson JH, Hesselink JR, Kennedy CJ, Richman DD, Spector SA, et al. Evidence for early central nervous system involvement in the acquired immunodeficiency syndrome (AIDS) and other human immunodeficiency viruses (HIV) infections: studies with neuropsychologic testing and magnetic resonance imaging. Ann Intern Med. 1987;107(6):828–36.

    CAS  PubMed  Google Scholar 

  33. Reis AS, Paineiras-Domingos LL, Moreira-Marconi E, Moura-Fernandes MC, Quinart H, Boyer FC, et al. Body composition in metabolic syndrome: proposal of a protocol for a randomized clinical trial evaluating the effect of whole-body vibration exercise. Braz J Health Biomed Sci. 2019;18(103):33–40.

    Google Scholar 

  34. Hofer J, Niebauer J. Cardiovascular risk factors: lipids and lifestyle changes. Arch Med Sci. 2007;3(4A):S69.

    Google Scholar 

  35. Lim S, Eckel RH. Pharmacological treatment and therapeutic perspectives of metabolic syndrome. Rev Endocr Metab Disord. 2014;15(4):329–41.

    CAS  PubMed  Google Scholar 

  36. Takeuchi H, Saitoh S, Takagi S, Ohnishi H, Ohhata J, Isobe T, et al. Metabolic syndrome and cardiac disease in Japanese men: applicability of the concept of the metabolic syndrome defined by the National Cholesterol Education Program–Adult Treatment Panel III to Japanese men—the Tanno and Sobetsu study. Hypertens Res. 2005;28(3):203–8.

    PubMed  Google Scholar 

  37. Grundy SM. Metabolic syndrome scientific statement by the American heart association and the national heart, lung, and blood institute. Am Heart Assoc. 2005. p. 2243–4.

  38. Skilton MR, Moulin P, Sérusclat A, Nony P, Bonnet F. A comparison of the NCEP-ATP III, IDF and AHA/NHLBI metabolic syndrome definitions with relation to early carotid atherosclerosis in subjects with hypercholesterolemia or at risk of CVD: evidence for sex-specific differences. Atherosclerosis. 2007;190(2):416–22.

    CAS  PubMed  Google Scholar 

  39. Tarp J. Epidemiological relationships between physical activity, fitness, and adiposity with cardiometabolic risk factors in youth. Department of Sports Science and Clinical Biomechanics. Denmark: University of Southern Denmark; 2018.

  40. Henry-Okafor QO. Effect of obesity on the traditional and emerging cardiovascular disease risk factors in African American women. Nursing. Memphis: University of Tennessee Health Science Center; 2009. p. 93.

  41. Torrance T. Sleep, Shiftwork adaptation, autonomic dysfunction, and metabolic syndrome. Epidemiology and Biostatistics. Columbia: University of South Carolina; 2018. p. 170.

  42. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109(3):433–8.

    PubMed  Google Scholar 

  43. Rider OJ, Asaad M, Ntusi N, Wainwright E, Clutton G, Hancock G, et al. HIV is an independent predictor of aortic stiffness. Journal of cardiovascular magnetic resonance: official journal of the Society for Cardiovascular Magnetic. Resonance. 2014;16:57. https://doi.org/10.1186/s12968-014-0057-1.

    Article  Google Scholar 

  44. Raposo MA, Armiliato GNA, Guimaraes NS, Caram CA, Silveira RDS, Tupinambas U. Metabolic disorders and cardiovascular risk in people living with HIV/AIDS without the use of antiretroviral therapy. Rev Soc Bras Med Trop. 2017;50(5):598–606. https://doi.org/10.1590/0037-8682-0258-2017.

    Article  PubMed  Google Scholar 

  45. Jarrett OD, Wanke CA, Ruthazer R, Bica I, Isaac R, Knox TA. Metabolic syndrome predicts all-cause mortality in persons with human immunodeficiency virus. AIDS Patient Care STDs. 2013;27(5):266–71. https://doi.org/10.1089/apc.2012.0402.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Silva EF, Bassichetto KC, Lewi DS. Lipid profile, cardiovascular risk factors, and metabolic syndrome in a group of AIDS patients. Arq Bras Cardiol. 2009;93(2):113–8.

    PubMed  Google Scholar 

  47. Krishnan S, Schouten JT, Atkinson B, Brown T, Wohl D, McComsey GA, et al. Metabolic syndrome before and after initiation of antiretroviral therapy in treatment-naive HIV-infected individuals. J Acquir Immune Defic Syndr. 2012;61(3):381–9. https://doi.org/10.1097/QAI.0b013e3182690e3c.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Signorini DJHP, Monteiro MCM, Andrade MdFCd, Signorini DH, Eyer-Silva WdA. What should we know about metabolic syndrome and lipodystrophy in AIDS? Rev Assoc Med Bras. 2012;58(1):70–5.

  49. Samaras K, Wand H, Law M, Emery S, Cooper D, Carr A. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and hypoadiponectinemia. Diabetes Care. 2007;30(1):113–9.

    CAS  PubMed  Google Scholar 

  50. Sawadogo A, Sanou S, Hema A, Kamboule BE, Kabore NF, Sore I, et al. Metabolic syndrome and cardiovascular risk patients under antiretrovirals in a day hospital at Bobo-Dioulasso (Burkina Faso). Bulletin de la Societe de pathologie exotique (1990). 2014;107(3):151–8. https://doi.org/10.1007/s13149-014-0371-8.

    Article  CAS  Google Scholar 

  51. Jantarapakde J, Phanuphak N, Chaturawit C, Pengnonyang S, Mathajittiphan P, Takamtha P, et al. Prevalence of metabolic syndrome among antiretroviral-naive and antiretroviral-experienced HIV-1 infected Thai adults. AIDS Patient Care STDs. 2014;28(7):331–40. https://doi.org/10.1089/apc.2013.0294.

    Article  PubMed  Google Scholar 

  52. Dias RFG, Bento LO, Tavares C, Ranes Filho H, Silva M, Moraes LC, et al. Epidemiological and clinical profile of HIV-infected patients from Southwestern Goias state, Brazil. Rev Inst Med Trop Sao Paulo. 2018;60:e34. https://doi.org/10.1590/s1678-9946201860034.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Cahn P, Leite O, Rosales A, Cabello R, Alvarez CA, Seas C, et al. Metabolic profile and cardiovascular risk factors among Latin American HIV-infected patients receiving HAART. Braz J Infect Dis: an official publication of the Brazilian Society of Infectious Diseases. 2010;14(2):158–66.

    CAS  Google Scholar 

  54. Akl LD, Valadares ALR, Moraes MJ, Pinto-Neto AM, Lagrutta B, Costa-Paiva L. Metabolic syndrome in HIV-infected middle-aged women on antiretroviral therapy: prevalence and associated factors. J Korean Med Sci. 2017;21(3):263–9. https://doi.org/10.1016/j.bjid.2017.02.003.

  55. Mondy K, Overton ET, Grubb J, Tong S, Seyfried W, Powderly W, et al. Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population. Clin Infect Dis. 2007;44(5):726–34.

    PubMed  Google Scholar 

  56. Alencastro PR, Fuchs SC, Wolff FH, Ikeda ML, Brandão AB, Barcellos NT. Independent predictors of metabolic syndrome in HIV-infected patients. AIDS Patient Care STDs. 2011;25(11):627–34.

    PubMed  Google Scholar 

  57. Martin A, Moore CL, Mallon PW, Hoy JF, Emery S, Belloso WH, et al. HIV lipodystrophy in participants randomized to lopinavir/ritonavir (LPV/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-line antiretroviral therapy. PLoS One. 2013;8(10):e77138. https://doi.org/10.1371/journal.pone.0077138.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Obirikorang C, Quaye L, Osei-Yeboah J, Odame EA, Asare I. Prevalence of metabolic syndrome among HIV-infected patients in Ghana: A cross-sectional study. Niger Med J: Journal of the Nigeria Medical Association. 2016;57(2):86–90. https://doi.org/10.4103/0300-1652.182082.

    Article  Google Scholar 

  59. Lundgren JD, Battegay M, Behrens G, De Wit S, Guaraldi G, Katlama C, et al. European AIDS clinical society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Medicine. 2008;9(2):72–81.

    CAS  PubMed  Google Scholar 

  60. Barbaro G, Di Lorenzo G, Cirelli A, Grisorio B, Lucchini A, Hazra C, et al. An open-label, prospective, observational study of the incidence of coronary artery disease in patients with HIV infection receiving highly active antiretroviral therapy. Clin Ther. 2003;25(9):2405–18.

    CAS  PubMed  Google Scholar 

  61. Mashinya F, Alberts M, Colebunders R. Assessment of cardiovascular risk factors in people with HIV infection treated with ART in rural South Africa: a cross-sectional study. AIDS Res Ther. 2015;12(1):42.

    PubMed  PubMed Central  Google Scholar 

  62. Berhane T, Yami A, Alemseged F, Yemane T, Hamza L, Kassim M, et al. Prevalence of lipodystrophy and metabolic syndrome among HIV positive individuals on Highly Active Anti-Retroviral treatment in Jimma, South West Ethiopia. Pan Afr Med J. 2012;13(1)1–14.

  63. Nery MW, Maria C, Martelli T, Turchi MD. Dyslipidemia in AIDS patients on highly active antiretroviral therapy. Braz J Infect Dis. 2011;15(2):151–5.

    CAS  PubMed  Google Scholar 

  64. Jette M, Sidney K, Blumchen G. Metabolic equivalents (METS) in exercise testing, exercise prescription, and evaluation of functional capacity. Clin Cardiol. 1990;13(8):555–65.

    CAS  PubMed  Google Scholar 

  65. Pitsavos C, Panagiotakos D, Weinem M, Stefanadis C. Diet, exercise and the metabolic syndrome. Rev Diabet Stud. 2006;3(3):118.

    PubMed  PubMed Central  Google Scholar 

  66. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med. 2005;352(1):48–62.

    CAS  PubMed  Google Scholar 

  67. Lee ST, Wong JE, Nik Shanita S, Ismail MN, Deurenberg P, Poh BK. Daily physical activity and screen time, but not other sedentary activities, are associated with measures of obesity during childhood. Int J Environ Res Public Health. 2015;12(1):146–61. https://doi.org/10.3390/ijerph120100146.

    Article  Google Scholar 

  68. Ford ES, Kohl HW, Mokdad AH, Ajani UA. Sedentary behavior, physical activity, and metabolic syndrome among US adults. Obesity. 2005;13(3):608–14.

    Google Scholar 

  69. Guimarães MMM, Greco DB, de Figueiredo SM, Fóscolo RB, de Oliveira AR, de Campos Machado LJ. High-sensitivity C-reactive protein levels in HIV-infected patients treated or not with antiretroviral drugs and their correlation with factors related to cardiovascular risk and HIV infection. Atherosclerosis. 2008;201(2):434–9.

    PubMed  Google Scholar 

  70. Després J-P. Body fat distribution and risk of cardiovascular disease. Circulation. 2012;126(10):1301–13.

    PubMed  Google Scholar 

  71. Iloeje U, Yuan Y, L'italien G, Mauskopf J, Holmberg S, Moorman A, et al. Protease inhibitor exposure and increased risk of cardiovascular disease in HIV-infected patients. HIV Medicine. 2005;6(1):37–44.

    CAS  PubMed  Google Scholar 

  72. Dillon DG, Gurdasani D, Riha J, Ekoru K, Asiki G, Mayanja BN, et al. Association of HIV and ART with cardiometabolic traits in sub-Saharan Africa: a systematic review and meta-analysis. Int J Epidemiol. 2013;42(6):1754–71. https://doi.org/10.1093/ije/dyt198.

    Article  PubMed  Google Scholar 

  73. Stanley TL, Grinspoon SK. Body composition and metabolic changes in HIV-infected patients. J Infect Dis. 2012;205(suppl_3):S383–S90.

    CAS  PubMed  PubMed Central  Google Scholar 

  74. Clark SJ, Gómez-Olivé FX, Houle B, Thorogood M, Klipstein-Grobusch K, Angotti N, et al. Cardiometabolic disease risk and HIV status in rural South Africa: establishing a baseline. BMC Public Health. 2015;15(1):135. https://doi.org/10.1186/s12889-015-1467-1.

    Article  PubMed  PubMed Central  Google Scholar 

  75. Manner IW, Trøseid M, Oektedalen O, Baekken M, Os I. Low nadir CD4 cell count predicts sustained hypertension in HIV-infected individuals. J Clin Hypertens. 2013;15(2):101–6.

    CAS  Google Scholar 

  76. Longenecker CT, Triant VA. Initiation of antiretroviral therapy at high CD4 counts: does it reduce the risk of cardiovascular disease? Curr Opin HIV AIDS. 2014;9(1):54–62. https://doi.org/10.1097/COH.0000000000000015.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Kaplan RC, Sinclair E, Landay AL, Lurain N, Sharrett AR, Gange SJ, et al. T cell activation predicts carotid artery stiffness among HIV-infected women. Atherosclerosis. 2011;217(1):207–13.

    CAS  PubMed  PubMed Central  Google Scholar 

  78. Carter V, Hoy J, Bailey M, Colman P, Nyulasi I, Mijch A. The prevalence of lipodystrophy in an ambulant HIV-infected population: it all depends on the definition. HIV Medicine. 2001;2(3):174–80.

    CAS  PubMed  Google Scholar 

  79. Gutierrez AD, Balasubramanyam A. Dysregulation of glucose metabolism in HIV patients: epidemiology, mechanisms, and management. Endocrine. 2012;41(1):1–10. https://doi.org/10.1007/s12020-011-9565-z.

    Article  CAS  PubMed  Google Scholar 

  80. Jotwani V, Li Y, Grunfeld C, Choi AI, Shlipak MG. Risk factors for ESRD in HIV-infected individuals: traditional and HIV-related factors. Am J Kidney Dis. 2012;59(5):628–35.

    PubMed  Google Scholar 

  81. Aboud M, Elgalib A, Pomeroy L, Panayiotakopoulos G, Skopelitis E, Kulasegaram R, et al. Cardiovascular risk evaluation and antiretroviral therapy effects in an HIV cohort: implications for clinical management: the CREATE 1 study. Int J Clin Pract. 2010;64(9):1252–9. https://doi.org/10.1111/j.1742-1241.2010.02424.x.

    Article  CAS  PubMed  Google Scholar 

  82. Odhiambo C, Davis J, Omolo B. Risk for cardiovascular disease in blacks with HIV/AIDS in America: a systematic review and meta-analysis. J Health Dispar Res Pract. 2017;10(2):8.

    Google Scholar 

  83. Sudano I, Spieker LE, Noll G, Corti R, Weber R, Lüscher TF. Cardiovascular disease in HIV infection. Am Heart J. 2006;151(6):1147–55. https://doi.org/10.1016/j.ahj.2005.07.030.

    Article  PubMed  Google Scholar 

  84. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007;92(7):2506–12.

    CAS  PubMed  Google Scholar 

  85. Després J-P, Lamarche B, Mauriège P, Cantin B, Dagenais GR, Moorjani S, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med. 1996;334(15):952–8. https://doi.org/10.1056/nejm199604113341504.

    Article  PubMed  Google Scholar 

  86. Triant VA. Epidemiology of coronary heart disease in HIV patients. Rev Cardiovasc Med. 2014;15(0 1):S1–8.

    PubMed  PubMed Central  Google Scholar 

  87. Islam F, Wu J, Jansson J, Wilson D. Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta–analysis. HIV medicine. 2012;13(8):453–68.

  88. Wilson P. HIV therapy and the risk for cardiovascular disease. HIV Medicine. 2012;13:453–68.

    PubMed  Google Scholar 

  89. Deeks SG, Phillips AN. Clinical review: HIV infection, antiretroviral treatment, aging, and non-AIDS related morbidity. BMJ. 2009;338:288–92.

    Google Scholar 

  90. Sterne J, May M, Bucher H, Ledergerber B, Furrer H, Cavassini M, et al. HAART and the heart: changes in coronary risk factors and implications for coronary risk in men starting antiretroviral therapy. J Intern Med. 2007;261(3):255–67.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We would like to thank Muhimbili University Health and Allied Sciences (MUHAS), Addis Ababa University (AAU), and the German Academic Exchanges Services (DAAD).

Funding

The fund for conducting the review was sponsored by DAAD.

Author information

Author notes

  1. Minyahil Woldu, Omary Minzi and Ephrem Engidawork contributed equally to this work.

Authors and Affiliations

  1. Department of Clinical Pharmacy and Pharmacology, Muhimbili University of Health and Allied Sciences, Dar es-Salaam, Tanzania

    Minyahil Woldu & Omary Minzi

  2. Department of Pharmacology and Clinical Pharmacy, Addis Ababa University, Churchill Avenue, 9086, Addis Ababa, Ethiopia

    Minyahil Woldu & Ephrem Engidawork

Authors
  1. Minyahil Woldu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Omary Minzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ephrem Engidawork
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

MA, OM, and EE made substantial contributions to the conception and design of the study, analyzed and interpreted the data, drafted the manuscript, revised the manuscript critically for important intellectual content. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Minyahil Woldu.

Ethics declarations

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Woldu, M., Minzi, O. & Engidawork, E. Prevalence of cardiometabolic syndrome in HIV-infected persons: a systematic review. J Diabetes Metab Disord 19, 1671–1683 (2020). https://doi.org/10.1007/s40200-020-00552-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40200-020-00552-x

Keywords

Search

Navigation